What if everything you thought you knew about treating an itchy patient was wrong?
At the 2026 Elevate Derm Rapids Conference, Victoria Garcia Albea, a dermatology nurse practitioner, sat down with world-renowned "itcholog" Dr. Yosipovitch to unpack the complex, neuroimmune world of chronic itch.
From why antihistamines fail to the strange reality of contagious scratching, here are the major clinical takeaways from their deep-dive conversation.
For decades, the standard knee-jerk reaction to a patient complaining of an itch was to prescribe an antihistamine. Dr. Yosipovitch urges clinicians to stop.
"I don’t state that itch is non-histaminergic," Dr. Yosipovitch clarifies. "Acute itch is. But the majority of itch that causes real suffering is chronic itch, and there, histamine has a very limited effect."
The nerve fibers transmitting chronic itch are entirely non-histaminergic. Instead, they are driven by pathways like PAR-2 (proteinase-activating receptor 2). Unless you are using a sedating antihistamine purely to knock a patient out for a sleepless night, these drugs are doing nothing to address the root cause of chronic itch—and they carry a heavy load of unwanted side effects.
When a patient presents with a severe, chronic itch but zero signs of an obvious inflammatory skin rash, it’s easy to panic and order every lab test under the sun. Dr. Yosipovitch recommends a targeted, logical approach instead:
Dr. Yosipovitch emphasizes a massive warning for the era of advanced therapeutics: biologics change what scabies looks like. Type 2 cytokines are the body’s natural defense against parasites. When patients are on drugs like dupilumab or nemolizumab, a scabies rash is entirely altered, making it incredibly easy to miss. The takeaway? Always rule out scabies before starting a patient on a biologic.
The science of itch is advancing rapidly, uncovering new molecules that bridge the gap between the nervous and immune systems.
It turns out that scratching when you see someone else scratch isn’t in your head—it’s in your brain.
Dr. Yosipovitch’s research demonstrated that visual cues trigger robust scratching behavior in both healthy individuals and patients with atopic eczema, though patients with atopic eczema are far more susceptible. Interestingly, fMRI tracking showed this isn't driven by the brain's yawning pathways (mirror neurons) but rather by the brain's reward and striatal areas.
(Fun fact from the episode: A dermatologist in North Carolina holds the world record for owning over 1,200 backscratchers. Dr. Yosipovitch declined a donation of the collection for his clinic, fearing it would trigger a psychological scratch-fest for his patients!)
When standard topicals fail, what is left in the toolbox? Dr. Yosipovitch shared a few specialized strategies:
For severe neuropathic itch, Dr. Yosipovitch utilizes a powerful compounded topical formula:
Safety Note: Keep application under 20% of the body surface area to prevent systemic absorption, and warn patients strictly against accidental ingestion!
Capsaicin is excellent at destroying the nerve fibers that transmit itch, but its initial "burning" phase leads to poor patient adherence. Dr. Yasepovich pairs it with EMLA cream. Because EMLA blocks sodium channels, it mitigates the initial burn and provides its own antipruritic effect. Note: Dr. Yosipovitch’s research noted that this pathway functions differently across demographics, showing significantly less efficacy in skin of color.
Itch was once an evolutionary survival mechanism that helped our ancestors scratch parasites off their skin. But when the system malfunctions, it causes profound suffering.
The good news? We are officially moving out of the dark ages of antihistamines and entering a golden era of targeted neuroimmune therapies. It is an exciting time to be an #Itcholog.
Listen to the entire podcast on Apple Podcasts or Spotify